Afuco™ Anti-ITGA4 and ITGB7 ADCC Therapeutic Antibody (Vedolizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human ITGA4+ITGB7. Vedolizumab (trade name vedolizumab) is a monoclonal antibody for the treatment of ulcerative colitis and Crohn's disease.It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name vedolizumab.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-H75 |
| Pricing | Inquiry |
| Host | Human |
| Target | ITGA4 and ITGB7 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |